Platform Validation & Discovery

About biotx

biotx.ai is a Munich-based, privately-held AI/ML biotech founded in 2018. The company has developed a proprietary causal inference platform that applies Mendelian randomization at an unprecedented scale, analyzing billions of data points from genome-wide association studies (GWAS) to establish high-confidence causal relationships between genes, biomarkers, and diseases. This platform is designed to de-risk drug discovery by providing genetic validation for targets and predicting clinical efficacy, addressing the high failure rates in Phase 2 trials. biotx.ai operates as a platform technology company, likely engaging in partnerships with pharmaceutical firms to leverage its causal maps and AI models.